It's the volume, stupid

Fear ruled the day again in biotech stock trading on 24 March over worries the Washington machine was seeking to seize control of the industry's pricing structure – a frenzy set off by a letter from three Democratic lawmakers sent late last week to Gilead Sciences over the pricing of its hepatitis C virus (HCV) medicine Sovaldi (sofosbuvir).